[1] 金克,胡青青,钱燕.新生儿肺透明膜病危险因素分析[J].中国全科医学,2017,20(1):161-163. [2] 彭峰,孙智勇.肺表面活性物质联合经鼻持续气道正压通气治疗早产儿肺透明膜病临床疗效观察[J].中国妇幼保健,2015,30(7):1141-1142. [3] 张兰.肺表面活性物质不同给药方法治疗新生儿肺透明膜病的效果观察[J].实用医院临床杂志,2016,13(1):69-71. [4] 邵肖梅,叶鸿瑁,丘小汕.实用新生儿学[M].4版.北京:北京人民卫生出版社,201l:395-398. [5] 韩梅盈,邹卉,梁莹莹,等.早产儿新生儿肺透明膜病高危因素的研究进展[J].山东医药,2015,55(37):101-103. [6] Jobe AH.50 years ago in the Journal of Pediatrics:surface properties and lipids from lungs of infants with hyaline membrane disease[J].J Pediatr,2015,166(2):301-301. [7] 淡云,卫文峰.肺表面活性物质联合鼻塞式持续气道正压通气治疗新生儿肺透明膜病的临床效果分析[J].实用心脑肺血管病杂志,2016,24(8):112-115. [8] 简惠娜,陈创鑫,赵少岚.沐舒坦与固尔苏应用于新生儿肺透明膜病的临床疗效对比分析[J].中国妇幼保健,2016,31(11):2319-2321. [9] 侯怡,魏丽蓉,李秀春.鼻塞式持续气道正压通气治疗新生儿肺透明膜病的疗效及护理对策[J].川北医学院学报,2017,32(2):297-299. [10] Duc GV, Engel K, Sinclair JC.Hemoglobin-oxygen affinity and erythrocyte 2,3-diphosphoglycerate (DPG) content in hyaline membrane disease (HMD) and cardiac malformations (CM)[J].Pediatric Research, 2015,4(5):467-467. [11] 高勤在.固尔苏气管内给药与N-CPAP联合治疗早产儿肺透明膜病疗效分析[J].中国妇幼保健,2015,30(3):483-484. [12] 谢伊玲.珂立苏联合鼻塞持续气道正压通气治疗新生儿肺透明膜病的效果及安全性[J].安徽医药,2015,19(10):2018-2019. [13] Ohtsuki Y, Fujita J, Yoshinouchi T, et al.Early stages of hyaline membrane formation detected in alveolar mouths in diffuse alveolar-damage-associated diseases:a detailed immunohistochemical study[J].Int J Surg Pathol,2015,23(7):524-30. [14] 易小青,向芬,余静.注射用牛肺表面活性剂联合经鼻持续正压通气治疗新生儿肺透明膜病的疗效及对呼吸力学的影响[J].医学综述,2016,22(24):4965-4968. |